特朗普宣布与礼来和诺和诺德达成降价协议，Ozempic和Wegovy经TrumpRx降至每月350美元
2025年11月6日，美国总统特朗普在华盛顿宣布，联邦政府已与礼来公司（Eli Lilly）和诺和诺德公司（Novo Nordisk）达成协议，大幅降低美国人购买多种常用处方药的价格。白宫说，协议涉及的两家公司的相关药物是美国年度支出最高的两类药物，用于帮助患有糖尿病、心脏病、肥胖等疾病的成年人。
按协议，通过政府平台TrumpRx购买时，Ozempic和Wegovy的价格将分别从每月1,000美元和1,350美元降至350美元；Zepbound以及礼来在研口服药Orforglipron（如获批准）的价格将从每月1,086美元降至平均346美元。若美国食品药品管理局日后批准Wegovy片剂等口服GLP-1药物，其起始剂量在TrumpRx上的价格为每月150美元。
在联邦医疗保险（Medicare）下，Ozempic、Wegovy、Mounjaro和Zepbound的价格将定为245美元，受益人每月自付50美元；州医疗补助（Medicaid）项目也可按此价格获得这些药物。白宫说，这将使Medicare首次能为患有肥胖及相关合并症的患者承保Wegovy和Zepbound。
协议还降低了两家公司的其他药物价格：礼来的偏头痛药Emgality每支299美元、糖尿病药Trulicity每月389美元，诺和诺德的NovoLog与Tresiba等胰岛素产品每月35美元。两家公司还承诺，新药上市时保证最惠国价格，并扩大在美投资：诺和诺德追加100亿美元扩大美国本土布局，礼来在特朗普任内已宣布至少270亿美元的新增美国制造业投资。
白宫说，美国疾病控制与预防中心估计，美国成年人肥胖率约为40%。特朗普曾于2025年5月12日签署行政令，要求把美国处方药价格降至与其他发达国家相当的水平，并于7月31日致信多家药企提出要求；自9月30日以来，政府已宣布与五家大型药企达成同类协议。
Trump Announces Price Deals With Eli Lilly and Novo Nordisk, Cutting Ozempic and Wegovy to $350 a Month Through TrumpRx
On November 6, 2025, President Donald J. Trump announced in Washington that the federal government had reached agreements with Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for several widely used prescription drugs. The White House said the agreements cover the two drugs with the highest annual expenditures in the United States, which help adults struggling with diabetes, heart disease, obesity and other conditions.
Under the agreements, the prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through the government platform TrumpRx. The price of Zepbound, and of Eli Lilly's oral drug orforglipron if approved, will fall from $1,086 per month to an average of $346 through TrumpRx. If the Food and Drug Administration later approves the Wegovy pill or similar oral GLP-1 drugs, the initial dose of those drugs will be priced at $150 per month through TrumpRx.
Under Medicare, the prices of Ozempic, Wegovy, Mounjaro and Zepbound will be $245, with beneficiaries paying a co-pay of $50 per month, and state Medicaid programs will also have access to these medications at these prices. The White House said the lower prices will enable Medicare to cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.
The agreements also cut prices for other medicines from the two companies: Eli Lilly's migraine treatment Emgality at $299 per pen, its diabetes medicine Trulicity at $389 per month, and Novo Nordisk insulin products including NovoLog and Tresiba at $35 per month of supply. Both companies will guarantee most-favored-nation prices on new medicines they bring to market and expand investment in the United States: Novo Nordisk committed an additional $10 billion to strengthen its domestic footprint, and Eli Lilly has announced at least $27 billion in new U.S. manufacturing investments under President Trump.
The White House said the Centers for Disease Control and Prevention estimates the prevalence of obesity among American adults to be 40 percent. On May 12, 2025, President Trump signed an executive order directing that American drug prices be brought in line with those paid by similar nations, and on July 31 he sent letters to leading manufacturers setting out the steps required. Since September 30, 2025, the administration has announced five such deals with major pharmaceutical manufacturers.
来源：白宫
发布：GSM·美国（发布链接）
图片来源：图：位于华盛顿的美国卫生与公众服务部总部休伯特·汉弗莱大楼（资料照片）。ajay_suresh摄，CC BY 2.0，经Wikimedia Commons；联邦固定图库同源图。 / Photo: The Hubert H. Humphrey Building, headquarters of the U.S. Department of Health and Human Services in Washington (file photo). By ajay_suresh, CC BY 2.0, via Wikimedia Commons; federal fixed image library image.
GSM Global · 本篇英文版 English edition of this story
